Patient perspectives on switching disease-modifying therapies in the NARCOMS registry

Amber R Salter1 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USACorrespondence[email protected]

Ruth Ann Marrie2 Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada;3 Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Neetu Agashivala4 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

Daniel A Belletti4 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

Edward Kim4 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

Gary R Cutter1 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

Stacey S Cofield1 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

Tuula Tyry5 Division of Neurology, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

show all

Figures & data

Figure 1 Response options for specific questions in the NARCOMS Patient’s Perspective survey.

Notes: (A) Decision (asked of all participants). (B) Discussion (asked only of participant-initiated switchers).
Abbreviations: JCV, John Cunningham virus; NARCOMS, North American Research Committee on Multiple Sclerosis; PML, progressive multifocal leukoencephalopathy.

Table 1 Sample characteristics

Download CSV Display Table

Figure 2 Cohort selection diagram.

Abbreviations: IM, intramuscular; SC, subcutaneous.

Table 2 Comparison of demographic and clinical factors between participant- and physician-initiated switchers

Download CSV Display Table

Table 3 Primary reason for switching therapy by current and most recent past therapy

Download CSV Display Table

Figure 3 Relapse activity and reported symptom worsening by DMT group and initiating group.

Notes: (A) Proportion with no reported relapse activity in the year prior to switch within the current DMT group by initiating group (physician or participant) (P=0.009). (B) Proportion with no reported symptom worsening in the year prior to switch within the current DMT group by initiating group (physician or participant) (P=0.15).

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry

Table 1 Sample characteristics

Table 2 Comparison of demographic and clinical factors between participant- and physician-initiated switchers

Table 3 Primary reason for switching therapy by current and most recent past therapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry

Figures & data

Table 1 Sample characteristics

Table 2 Comparison of demographic and clinical factors between participant- and physician-initiated switchers

Table 3 Primary reason for switching therapy by current and most recent past therapy

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date